Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced today that it has exercised its option to acquire Myonexus Therapeutics, a clinical-stage biotechnology company developing transformative gene ...
Sarepta is determined to stay at the forefront of genetic medicines for muscular dystrophies and to that end has signed another R&D deal—this time with Myonexus Therapeutics—and taken an option on buying the company.